61
Participants
Start Date
November 30, 2008
Primary Completion Date
March 31, 2012
Study Completion Date
March 31, 2012
Administration of quetiapine XR
The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
Tri-Service General Hospital, National Defense Medical Center, Taipei
Collaborators (1)
AstraZeneca
INDUSTRY
Tri-Service General Hospital
OTHER